10 / 18
Page 41
O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n
Pharma Congress 2018 & Molecular Medicine 2018
& Psychiatric Disorders 2018
Asian Journal of Biomedical and Pharmaceutical Sciences
|
ISSN: 2249-622X
|
Volume 8
International Conference on
PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS
19
th
International Conference on
CELLULAR AND MOLECULAR MEDICINE
19
th
Annual Congress on
PSYCHIATRY AND PSYCHIATRIC DISORDERS
&
&
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
alliedacademies.comYEARS
Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C3-009
HISTOPATHOLOGY – FROM SUPPORTIVE TO DOMINANT TOOL IN
PRECLINICAL EFFICACY STUDIES
Emmanual Loeb
Patho-Logica, Israel
T
he histopathological evaluation in preclinical efficacy studies is often biased due to unsuitable methods, lack of standardiza-
tion and use of qualitative observations. A comparison between studies is difficult because of the diversity of assays used to
assess a similar tissue and injury. In addition, the need for a specifically trained expert to analyze the histological data also leads
to the lesser use of histology in the R&D of drug development. The aim of this presentation is to demonstrate the contribution
of quantitative measures and advanced image analysis tools to seek for an unbiased histopathological evaluation. By choosing
the most relevant parameters, that best suit the scientific questions being addressed, investigators may overcome the risk of in-
correct interpretation. Examples of a quantitative assessment of multiple histological features for various injuries will be shown,
indicating the advantages of using a computerized image analysis system for densitometry and for morphometric analysis. The
latter is critical for the assessment of the extent of tissue injury in efficacy studies in experimental animal models. Attention will
be drawn to lung tissue and free-floating brain sections. Quality assurance measures support the histopathological analysis,
contributing to the reduction of errors and to the ability to detect subtle differences between treatment groups. In summary, the
scientific impact of histopathology in preclinical efficacy studies at present, is increasing and becoming dominant due to the
greater use of advanced methodology and quantitative analysis.